News2020-05-23T14:50:18+00:00

Read Our Recent News

NanoMab receives MHRA approval to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging.

London, November 4th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product. The study (“PELICAN”) will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The [...]

November 5th, 2020|

NanoMab and OncoBeta outline the pathway to a Strategic Alliance and Supply Agreement, focused on the secure supply of Rhenium-188 for NanoMab’s range of Therapeutic Radiopharmaceuticals

London, October 27th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier of Tungsten-188/ Rhenium-188 generators for the production of high-energy beta emitting Rhenium-188, as well as a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers. These Heads of Terms will precede a Strategic Alliance and Supply Agreement for developing Rhenium-188 API solutions, which are suitable for [...]

October 27th, 2020|

NanoMab announces the commencement of the NM-01 mechanistic study (SPECT/CT radiotracer) for non-small cell lung cancer patients.

London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer. Professor Gary Cook, Professor of PET Imaging at King’s College London said, “We have scanned our first participant; the images I reviewed are of excellent quality and clearly show the heterogeneity of PD-L1 expression [...]

October 9th, 2020|

NanoMab Submits a request to the MHRA to commence a Phase 2 Clinical Study to investigate PD-L1 expression using its NM-01 product as a tool for non-invasive in vivo imaging

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using 99mTc-NM-01 as a SPECT/CT radiotracer and its correlation to PD-L1 expression results based on routine immunohistochemical (IHC) testing in biopsy diagnostic specimens. The study will be carried out [...]

September 10th, 2020|

Contact Us With Any Questions

Please do not hesitate to get in touch with any questions.

CONTACT US